Antibody-Comb Polymer Conjugate for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for attaching effector molecules to antibodies lack efficiency in delivering therapeutic agents specifically to therapeutic targets, such as tumor cells, and do not adequately address the issues of immunogenicity and solubility.
Innovation Solution
Development of antibody-comb polymer conjugates that incorporate effector molecules and solubilizing moieties, where the comb polymer is attached to antibodies, enhancing specificity and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If effector molecules are attached to antibodies using direct attachment or linker methods, then the binding specificity is maintained, but the delivery efficiency to therapeutic targets is insufficient and immunogenicity increases
Solution Approach 1:
A comb polymer acts as an intermediary structure between the antibody and effector molecules. The polymer backbone provides a scaffold that attaches to the antibody via a linker, while multiple effector molecules are attached to the polymer's side chains. This intermediary structure improves delivery efficiency through enhanced stability and controlled release, while the polymer's hydrophilic nature reduces immunogenicity compared to direct attachment methods.
Solution Approach 2:
The invention creates a composite conjugate structure combining antibody, linker, comb polymer, and effector molecules. This multi-component composite allows optimization of each component's function: the antibody provides target specificity, the linker enables controlled attachment, the comb polymer enhances stability and reduces immunogenicity, and the effector molecules provide therapeutic activity. The composite structure resolves the contradiction by integrating multiple functional elements that collectively improve delivery efficiency while mitigating harmful immune responses.
2Reliability
If effector molecules are attached to antibodies, then therapeutic delivery is achieved, but solubility of the conjugate is reduced
Solution Approach 1:
The comb polymer's chemical structure parameters are optimized to balance therapeutic delivery and solubility. The polymer incorporates hydrophilic groups (such as carboxylic acid, hydroxyl, or amine groups) at specific ratios along the backbone and side chains. By adjusting the polymer's molecular weight, composition, and functional group distribution, the conjugate maintains adequate solubility in physiological conditions while preserving effector molecule delivery capability.
Solution Approach 2:
Different regions of the comb polymer have different functional qualities: the backbone provides structural stability and antibody attachment, while the side chains contain solubilizing groups that enhance water solubility. Effector molecules are attached at specific locations on the polymer structure where they can be delivered effectively without compromising overall solubility. This local differentiation of functional qualities allows the conjugate to achieve both therapeutic delivery and solubility requirements simultaneously.
3Productivity
If multiple effector molecules are attached to antibodies, then delivery capacity is increased, but the complexity of the conjugate structure increases
Solution Approach 1:
The comb polymer structure segments the attachment of multiple effector molecules into an organized architecture. Instead of randomly attaching effector molecules directly to the antibody (which would create high complexity), the polymer backbone serves as a modular scaffold with repeating units. Each unit can independently carry an effector molecule, allowing systematic control over the number and arrangement of effectors. This segmented structure increases delivery capacity while maintaining manageable structural complexity through regular, predictable patterns.
4Duration of action of stationary object
If PEG is attached to proteins to reduce immunogenicity and increase half-life, then circulating half-life is increased, but the efficiency of delivering effector molecules to targets is reduced
Solution Approach 1:
The invention transitions from linear PEG attachment (single dimension) to a comb polymer architecture (three-dimensional structure). The comb polymer extends outward from the antibody in multiple directions, creating a volumetric distribution of effector molecules. This dimensional change allows the conjugate to maintain extended circulation half-life (like PEGylated proteins) while simultaneously improving delivery efficiency through the polymer's ability to present multiple effector molecules in spatial configurations that facilitate target binding and drug release.
Data Source
AI summary
The present invention provides a process for producing a comb polymer comprising the steps of : a) providing: (i) (w+z) molar equivalents of a monomer; (ii) one molar equivalent of an initiator compound of formula (IX), wherein B3 represents a halogen, B2 represents H or a halogen, Y1 represents a group capable of attaching the residue of an antibody or fragment thereof or capable of being converted into such a group, L represents a linker group, y is 1, 2 or 3, w is at least 1 and z is 0 or greater; (iii) a catalyst capable of catalysing the polymerisation of a plurality of the monomers to produce the comb polymer; and b) causing the catalyst to catalyse, in combination with the initiator, the polymerisation of a plurality of the monomers (i) to produce the comb polymer.